Imatinib Mesylate Inhibits CD4+CD25+Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL−Tumors-Reference-Cited by-同舟云学术

Imatinib Mesylate Inhibits CD4+CD25+Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL−Tumors

Published:2008-11-03 Issue:10 Volume:181 Page:6955-6963
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Larmonier Nicolas,Janikashvili Nona,LaCasse Collin James,Larmonier Claire Billerey,Cantrell Jessica,Situ Elaine,Lundeen Tamara,Bonnotte Bernard,Katsanis Emmanuel

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference50 articles.

1. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

2. Imatinib Mesylate — A New Oral Targeted Therapy

3. CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

4. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

5. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells;ACS Applied Materials & Interfaces;2024-09-06

2. Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy;International Journal of Cancer;2024-08-22

3. Prognostic Significance of Regulatory T-Cells and PD-1 + CD8 T-Cells in Chronic Myeloid Leukemia Patients Treated with Generic Imatinib;Indian Journal of Hematology and Blood Transfusion;2024-08-20

4. A case of psoriasiform eruption developed during imatinib therapy;Anais Brasileiros de Dermatologia;2024-08

5. Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy;Bioactive Materials;2024-01